Document is current

Article History

Received: 11 July 2024

Accepted: 1 December 2024

First Online: 2 January 2025

Competing interests

: This research was supported by Grid Therapeutics. Drs. Patz, Campa, and Gottlin have affiliation with both Grid Therapeutics and Duke University. JMC reports trial funding from Bristol-Myers Squibb, Genentech, Spectrum, Adaptimmune, AbbVie, Moderna, GlaxoSmithKline, Array, AstraZeneca, Grid Therapeutics, Abel Zeta, Pfizer; advisory/consulting from AstraZeneca, Merck, Pfizer, Spectrum, Genentech, Novartis, Turning Point, G1 Therapeutics, Vivacitas, Omega, Amgen, Corbus, Sanofi; speaking and travel from Merck and Amgen; DSMB from BioThera and G1 Therapeutics. GS reports speaking for Astra-Zeneca, consulting for Daiichi Sankyo, board member for Florida chapter of ASCO, and stock Options and consulting compensation for Onc.AI. HM reports advisory board for AstraZeneca, Genentech, and Daiichi Sankyo; and research funding from AstraZeneca. TS reports clinical trial funding from AstraZeneca, Seagen, Mirati Therapeutics, Genentech/Roche, Nuvalent, Inc.; consulting from Takeda, G1 Therapeutics, Spectrum Pharmaceuticals, Gilead Sciences, AstraZeneca, Coherus Biosciences, Blueprint Medicines, Boehringer Ingelheim, Pfizer, Abbvie; travel funding from Pfizer; DSMB participation from Genentech. NR reports advisory compensation from BMS, Merck, Jazz, Genentech, Daiichi, Regeneron, ABBVIE, research funding Merck, Regeneron, and speaking from Jazz. JC reports Scientific Advisor from Actimed, Enzychem, Gen Sci, Pfizer, Tensegrity; DSMB Member of BioAtla, G1 Therapeutics; PI/Institutional Research Funding for AstraZeneca, Helsinn, Pfizer, NCI/NCTN; Publications Committee of Amgen, Frensenius-Kabi, G1, Pfizer. GS reports advisory board from EMD Serono, BMS, Merck, Seattle Genetics, Astellas, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, Eli Lilly, Loxo Oncology, Vial, Aktis, Daiichi-Sankyo; Consultant/Scientific Advisory Board (SAB)/trial steering committee: Syapse, Merck, Servier, Syncorp, Ellipses; Research Support to institution from EMD Serono, Jazz Therapeutics, Bayer, Sumitomo Pharma, Blue Earth Diagnostics; Speaker from Seagen, Gilead, Natera, Exelixis, Janssen, Astellas, Bayer, Aveo, Pfizer, Merck; Data safety monitoring committee (honorarium) from Mereo; Employment: Spouse employed by Myriad, Exact Sciences; and Travel: BMS, Astellas. SB receives support from the National Institutes of Health, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), serves on an NIH DSMB, and consults for UCB (Morrisville, NC, USA), CARRA, and Rutgers University. Stephen Balevic is a member of the American College of Rheumatology, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), Alpha Omega Alpha, the American Society of Clinical Investigators, and the Society for Pediatric Research, and served as the Assistant Scientific Director for CARRAAN reports funding from Genentech, Genmab, MedImmune/AstraZeneca, Seattle Genetics; consulting from Sanofi, Promega; SAB from Leap Therapeutics; NCI Chair, Core Correlatives Sciences Committee (NCTN-CCSC); and patents of No 925592 and No. 62/337,633. MC is a founder of Grid Therapeutics, LLC and is on the advisory board. EBG is a founder of Grid Therapeutics, LLC. SA reports being member of scientific advisory boards for Cellepus Therapeutics (and Co-founder), Leap Therapeutics, Guardian Bio, Immutep, Shoreline Therapeutics, Tubulis, Xilis, Glympse Bio, Achilles Therapeutics, Memgen, RAPT Biotherapeutics. EFP is a founder, CEO and on the BOD of Grid Therapeutics, LLC. All other authors report no competing interests.